A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

@article{Gordon2015AP2,
  title={A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.},
  author={Kenneth B. Gordon and Kristina Callis Duffin and R Bissonnette and Joerg Christoph Prinz and Yasmine S Wasfi and Shu Zhen Li and Yaung-Kaung Shen and Philippe O. Szapary and Bruce P Randazzo and K Reich},
  journal={The New England journal of medicine},
  year={2015},
  volume={373 2},
  pages={136-44}
}
BACKGROUND Little is known about the effect of specific anti-interleukin-23 therapy, as compared with established anti-tumor necrosis factor therapies, for the treatment of moderate-to-severe plaque psoriasis. METHODS In a 52-week, phase 2, dose-ranging, randomized, double-blind, placebo-controlled, active-comparator trial, we compared guselkumab (CNTO 1959), an anti-interleukin-23 monoclonal antibody, with adalimumab in patients with moderate-to-severe plaque psoriasis. A total of 293… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 19 times over the past 90 days. VIEW TWEETS